Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
Crossref DOI link: https://doi.org/10.1007/s40273-015-0332-5
Published Online: 2015-10-30
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Herring, William
Pearson, Isobel
Purser, Molly
Nakhaipour, Hamid Reza
Haiderali, Amin
Wolowacz, Sorrel
Jayasundara, Kavisha
Funding for this research was provided by:
GlaxoSmithKline
Novartis Pharmaceuticals Canada Inc.
Text and Data Mining valid from 2015-10-30